2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2008060579v1 20/5/1094    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ramirez, S. P.B. Articles by Port, F. K. Search for Related Content PubMed PubMed Citation Articles by Ramirez, S. P.B. Articles by Port, F. K.

Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients

Sylvia P.B. Ramirez^*, Justin M. Albert^*, Margaret J. Blayney^*, Francesca Tentori^*, David A. Goodkin^*, Robert A. Wolfe^*, Eric W. Young, George R. Bailie, Ronald L. Pisoni^* and Friedrich K. Port^*

^* Arbor Research Collaborative for Health and Veterans Affairs Medical Center/University of Michigan, Ann Arbor, Michigan; and Albany College of Pharmacy, Albany, New York

Correspondence: Dr. Friedrich K. Port, Arbor Research Collaborative for Health, 315 W. Huron, Suite 360; Ann Arbor, MI 48103. Phone: 734-665-4108; Fax: 734-665-2103; E-mail: friedrich.port{at}arborresearch.org

Received for publication June 6, 2008. Accepted for publication December 3, 2008.

Recent studies have associated rosiglitazone, a thiazolidinedione drug, with adverse cardiovascular outcomes in the general population with diabetes. Using data from the Dialysis Outcomes and Practice Patterns Study in the United States, we examined cardiovascular hospitalization and mortality associated with prescription of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialysis patients who were followed for a median of 1.1 yr. We assessed mortality risk using Cox models in patient-level and dialysis facility–level analyses that used the facility proportion of patients on rosiglitazone as the predictor (instrumental variable approach) and adjusted the models for demographics, comorbid conditions, laboratory values, and achieved dialysis dosage. Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitazone had significantly higher all-cause (hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.05 to 1.82) and cardiovascular (HR 1.59; 95% CI 1.14 to 2.22) mortality, and their adjusted HR for hospitalization with myocardial infarction was 3.5-fold higher (P = 0.02). We did not observe similar associations in a secondary analysis evaluating pioglitazone. By the instrumental variable approach, facilities with more than the median adjusted percentage (6.2%) of patients who had diabetes and were prescribed rosiglitazone had significantly higher all-cause mortality (HR 1.36; 95% CI 1.15 to 1.62) and cardiovascular mortality (HR 1.42; 95% CI 1.07 to 1.88) than facilities with less than the median expected percentage prescribed rosiglitazone. Our practice-based findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cause mortality among hemodialysis patients with diabetes.

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673